qpcr
(2)
Feng Xuan
Feng Xuan is a Boston-based scientist-entrepreneur and the co-founder and CEO of Spear Bio, a biotechnology company building ultra-sensitive immunoassays for protein research and early disease diagnostics. He invented the company's core SPEAR (Successive Proximity Extension Amplification Reaction) technology as a Technology Development Fellow at Harvard's Wyss Institute, translating a decade of research in molecular and immuno-diagnostics into a platform that can measure minute quantities of protein biomarkers from sub-microliter samples. Under his leadership, Spear Bio raised an oversubscribed $45 million Series A in 2024 and earned FDA Breakthrough Device Designation for a blood-based pTau 217 test aimed at early Alzheimer's disease detection.
Hiranjith H
Hiranjith H (also Hiranjith GH) is the Chief Business Officer of Algorithmic Biologics, a Bengaluru-founded deeptech startup that embeds algorithms inside test tubes to make molecular testing dramatically cheaper and faster. Based in the San Francisco Bay Area, he leads the company's commercial operations and US expansion. He spent more than a decade scaling MedGenome's research-services business in the US and earlier built commercialization and analytics strategy for life-sciences clients at Novartis, ZS Associates, and Accenture Management Consulting.